Merck signs ADC deal with Sutro Biopharma
Sutro Biopharma Inc. (cancer antibodies) licensed Merck KGAA’s EMD Serono Inc. rights to develop and commercialize its antibody-drug conjugates (ADCs) against several undisclosed oncology targets.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.